M 9657
Alternative Names: M-9657Latest Information Update: 19 Jun 2024
At a glance
- Originator EMD Serono
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Apr 2023 Preclinical trials in Cancer in USA (unspecified route)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)